Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24856272 | 0.88 | KDM4E (0.43) | ALDH1A1KDM4EALOX15SIGMAR1MEN1 | |
| SCHEMBL16254537 | 0.88 | KDM4E (0.43) | ALDH1A1KDM4EALOX15SIGMAR1MEN1 | |
| SCHEMBL19797927 | 0.85 | SIGMAR1 (0.35) | SIGMAR1HRH3 | |
| SCHEMBL14355437 | 0.85 | — | — | |
| SCHEMBL11916112 | 0.83 | SIGMAR1 (0.42) | ALDH1A1KDM4ETSHRALOX15SIGMAR1 | |
| SCHEMBL19936629 | 0.77 | ALDH1A1 (0.37) | ALDH1A1KDM4ETSHRALOX15KDM2B | |
| SCHEMBL16675697 | 0.77 | ALDH1A1 (0.37) | ALDH1A1KDM4ETSHRALOX15KDM2B | |
| SCHEMBL117945 | 0.76 | SIGMAR1 (0.41) | TSHRSIGMAR1MEN1KMT2A | |
| SCHEMBL11916119 | 0.76 | SIGMAR1 (0.37) | ALDH1A1KDM4EALOX15SIGMAR1HRH3 | |
| SCHEMBL22995523 | 0.76 | ALDH1A1 (0.39) | ALDH1A1KDM4ETSHRALOX15KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202354-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | ALDH1A1 656/4885KDM4E 19/4885TSHR 4578/4885 |
| US-10202354-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | ALDH1A1 656/4885KDM4E 19/4885TSHR 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.